olaparib,bevacizumab
astrazeneca,merck,roche
['ovarian', 'lynparza', 'bevacizumab', 'paola-1']
in the paola-1 trial, median os in #lynparza plus #bevacizumab was 56.5 months versus 51.6 months in patients on bevacizumab alone #ovariancancer #patients irrespective of hrd status. lynparza showed no statistically significant improvement. 
iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma